Patents by Inventor David Thomas Parker

David Thomas Parker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Organic compounds and their uses
    Patent number: 7825152
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: April 9, 2007
    Date of Patent: November 2, 2010
    Assignee: Novartis AG
    Inventors: Trixi Brandl, Jiping Fu, Francois Lenoir, David Thomas Parker, Michael Patane, Branko Radetich, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic, Aregahegn Yifru, Rui Zheng
  • Organic Compounds and their uses
    Publication number: 20100240638
    Abstract: The present application describes macrocyclic compounds of formula (I) with NS3 protease inhibitory activity for treating hepatitis C virus infection.
    Type: Application
    Filed: February 19, 2008
    Publication date: September 23, 2010
    Inventors: Shawn D. Britt, Jiping Fu, David Thomas Parker, Michiael Patane, Parkash Raman, Branko Radetich, Mohindra Seepersaud, Aregahegn Yifru, Rui Zheng, Trixi Brand, Sylvain Cottens, Claus Ehrhardt, Stefan Andreas Randl, Pascal Rigollier, Nikolaus Schiering, Oliver Simic
  • ORGANIC COMPOUNDS AND THEIR USES
    Publication number: 20100204159
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: September 11, 2007
    Publication date: August 12, 2010
    Inventors: Trixl Brandl, Sylvain Cottens, Claus Ehrhardt, Jiping Fu, Subramanian Karur, David Thomas Parker, Michael A. Patane, Prakash Raman, Stefan Andreas Randl, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • ORGANIC COMPOUNDS AND THEIR USES
    Publication number: 20100120872
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: September 11, 2009
    Publication date: May 13, 2010
    Applicant: Novartis AG
    Inventors: Markus Rolf Dobler, Francois Lenoir, David Thomas Parker, Yunshan Peng, Grazia Piizzi, Sompong Wattanasin
  • Organic Compounds and Their Uses
    Publication number: 20090137495
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: October 10, 2008
    Publication date: May 28, 2009
    Inventors: Shawn D. Britt, Lech Andrzej Ciszewski, Jiping Fu, Subramanian Karur, Yugang Liu, Peichao Lu, David Thomas Parker, Mahavir Prashad, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Aregahegn Yifru, Rui Zheng
  • Certain azacycloalkyl substituted acetic acid derivatives
    Publication number: 20040235896
    Abstract: Compounds of the formula (I) wherein R represents OH or NHOH; R1 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl, or acyl derived from a carboxylic acid, from a carbonic acid, from a carbamic acid of from a sulfonic acid; R2 represents biarylsulfonyl or aryloxyarylsufonyl; R3 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl or acyl derived from a carboxylic acid, from a carbonic acid or form a carbamic acid; R4 and R5 represent independently hydrogen, lower alkyl, lower alkoxycarbonyl, aryl-lower alkyl or cycloalkyl-lower alkyl; m is zero, 1, 2 or 3; pharmaceutically acceptable prodrug derivatives thereof; pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; and their use for inhibiting matrix degrading metalloproteinases and preventing or treating matrix metalloproteinase dependent conditions in mammals.
    Type: Application
    Filed: May 13, 2004
    Publication date: November 25, 2004
    Inventors: Roger Aki Fujimoto, Leslie Wighton McQuire, Lauren G. Monovich, Philippe Nantermet, David Thomas Parker, Leslie Ann Robinson, Jerry W. Skiles, Ruben alberto Tommasi
  • Certain alpha-substituted arylsulfonamido acetohydroxamic acids
    Patent number: 5770624
    Abstract: Particularly the invention relates to the compounds of formula I ##STR1## wherein Ar represents carbocyclic aryl, heterocyclic aryl or biaryl;R.sub.1 represents lower alkyl, cycloalkyl, aryl-lower alkyl, lower alkoxy-lower alkyl, aryl, cycloalkyl-lower alkyl, halo-lower alkyl;R.sub.2 represents hydrogen or lower alkyl;R.sub.3 and R.sub.4 represent independently hydrogen, lower alkyl, lower alkoxy, halo, hydroxy, acyloxy, lower alkoxy-lower alkoxy, trifluoromethyl or cyano; or R.sub.3 and R.sub.4 together represent lower allylenedioxy;n represents an integer from 1 to 5;pharmaceutically acceptable prodrug derivatives; and pharmaceutically acceptable salts thereof; methods for preparation thereof;pharmaceutical compositions comprising said compounds; and a method of inhibiting TNF-alpha activity and matrix-degrading metalloproteinases in mammals using such compounds.
    Type: Grant
    Filed: December 10, 1996
    Date of Patent: June 23, 1998
    Assignee: Novartis Corp.
    Inventor: David Thomas Parker
  • Arylsulfonamido-substituted hydrodxamic acids
    Patent number: 5672615
    Abstract: Disclosed are the compounds of formula I ##STR1## wherein R and R.sub.1 together with the chain to which they are attached or R.sub.1 and R.sub.2 together with the carbon atom to which they are attached form a ring; pharmaceutically acceptable prodrug derivatives and pharmaceutically salts thereof; methods of preparation thereof; pharmaceutical compositions comprising said compounds; and a method of inhibiting matrix-degrading metalloproteinase and of treating matrix-degrading metalloproteinase dependent conditions in mammals using such compounds.
    Type: Grant
    Filed: March 11, 1996
    Date of Patent: September 30, 1997
    Assignee: Novartis Corporation
    Inventors: Lawrence J. MacPherson, David Thomas Parker